Integra Therapeutics to receive up to €10.5 million from European Commission for its FiCAT... 17/07/2024 Healthcare Access to innovation Rare diseases Advanced therapies EU projects This funding will enable Integra Therapeutics to launch its first gene therapy to treat a serious pediatric hepatic... Partners - Integra Therapeutics S.L.
Almirall and the Centre for Genomic Regulation (CRG) Advance Research on Atopic Dermatitis 02/07/2024 Healthcare Access to innovation Rare diseases The research objectives of this collaboration include the characterization of experimental models of AD to identity... Partners - Almirall
BCN HEALTH publishes a study evaluating the use of resources and medical costs of septic a... 01/07/2024 Healthcare Rare diseases The objective of this study was to review the characteristics of patients admitted with septic arthritis in Spanish... Partners - BCN Health
Oryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ... 26/06/2024 Healthcare Access to innovation Rare diseases Advanced therapies Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre. Partners - Oryzon Genomics
ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ... 14/06/2024 Healthcare Access to innovation Drug discovery Rare diseases Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed... Partners - Oryzon Genomics
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
BCN HEALTH publishes a study estimating the cost of thalassaemia care across the world 29/05/2024 Healthcare Rare diseases BCN HEALTH desarrolló un modelo de costes aplicable a nivel mundial para la atención de la talasemia. Partners - BCN Health
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Miramoon Pharma Receives Orphan Drug Designation for MP-004 28/05/2024 Healthcare Access to innovation Rare diseases Innovative drugs Orphan Drug Designation is a special status granted by the FDA to drugs that are intended to treat rare diseases or... Partners - Miramoon Pharma
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
